The FDA on March 30, 2016 approved DEFITELIO® for the treatment of adult and pediatric patients with hepatic Veno-Occlusive Disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction, following Hematopoietic Stem Cell Transplantation (HSCT). DEFITELIO® is a product of Jazz Pharmaceuticals, Inc.
Bottom Ad
Advertisement
Subscribe
